Broncus Shares Slide in Hong Kong Debut but Raises Almost $200 Million
Investing.com
Published Sep 24, 2021 01:08AM ET
By Gina Lee
Investing.com – Broncus Holding Corp. (HK:2216) made a disappointing debut on the Hong Kong Stock Exchange on Friday, but still raised HK$1.55 billion ($199.1 million) via its offering.
Shares were steady at HK$15.28 by 1:13 AM ET (5:13 AM GMT). Broncus had priced its IPO at HK$18.70 a share, the top end of its indicative range.
Goldman Sachs (NYSE:GS) (Asia) L.L.C. and Haitong International Securities Company Limited were joint sponsors and joint representatives.
Credit Suisse (SIX:CSGN) (Hong Kong) Limited joined the duo as joint global coordinator, joint bookrunner and joint lead manager.
CMB International Capital Limited, Huatai Financial Holdings (Hong Kong) Limited, China Industrial Securities International Capital Limited and CNCB (Hong Kong) Capital Limited also served as joint bookrunners and joint lead managers.
Broncus will use the offering proceeds for research and development and business expansion. It specializes in diagnosing and treating lung ailments.
Founded in 2012 and based in Hangzhou, the company develops interventional pulmonology products. It also has an integrated interventional pulmonology platform that improves the diagnosis and treatment effects of lung cancer and chronic obstructive pulmonary disease.
The company’s core products include the InterVapor thermal vapor energy ablation system and RF Generator + RF Ablation Catheter that specifically targets lung cancer.
Broncus posted net losses of $32.6 million for 2019 and $48.8 million for 2020, with revenue falling 59% in 2020. The company expects to continue incurring net losses as it boosts R&D efforts and commercializes its products.
It is the latest medical-related company to list in Hong Kong in 2021, including Acotec Scientific Holdings Ltd.'s (HK:6669) HK$1.53 billion IPO In August 2021 and Angelalign Technology Inc.'s (HK:6699) HK$2.72 billion IPO in June 2021.
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.